Zetagen Therapeutics, a clinical-stage biopharmaceutical company focused on treatments for metastatic bone cancers and osteologic interventions, has successfully secured $12,900,000 in new investment capital from investors. This funding round marks a significant milestone for the private company, enabling it to advance its innovative drug-eluting implant technology towards critical clinical trials. The capital infusion underscores investor confidence in Zetagen’s multi-patented approach to addressing unmet needs in bone health and cancer treatment.
Founded in 2015, Zetagen is dedicated to developing breakthrough innovations, most notably its ZetaMet™ technology. Exclusively licensed from the State University of New York in 2016, ZetaMet™ is a first-of-its-kind molecular pathway. Its design aims to suspend cancer progression, inhibit pain associated with metastatic bone disease, and regenerate bone tissue. This novel therapy, a drug-eluting implant, has successfully completed its preclinical trials and is now being prepared for its first human clinical trial, anticipated to commence in Q4 2021.
The newly raised $12.9 million will primarily be directed towards accelerating the development and clinical translation of the ZetaMet™ platform. This includes supporting the rigorous preparations and execution of its upcoming human clinical trial, a crucial step for any biopharmaceutical company. Additionally, the funding will fuel continued research and development efforts across Zetagen’s broader pipeline, which includes other oncologic treatments for Skeletal Related Events like ZetaMet Flowable™, as well as ancillary osteologic treatments such as ZetaFuse™, ZetaSet™, ZetaDent™, and ZetaBase™.
This investment empowers Zetagen Therapeutics to significantly progress its therapeutic candidates, moving closer to potentially offering new options for patients suffering from metastatic bone cancers and other osteologic conditions. With this secured capital, the company is well-positioned to drive its growth initiatives and expand its impact in the biopharmaceutical landscape, bringing its innovative technologies through the crucial stages of clinical development.
